Trial Profile
A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Menadione (Primary)
- Indications Exanthema
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 11 Nov 2020 Status changed from active, no longer recruiting to completed.
- 16 Oct 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
- 16 Oct 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2018.